NASDAQ:NVCT Nuvectis Pharma (NVCT) Stock Price, News & Analysis $6.40 -0.27 (-4.05%) (As of 09/16/2024 ET) Add Compare Share Share Today's Range$6.00▼$7.0450-Day Range$6.16▼$7.2352-Week Range$5.85▼$14.96Volume250,970 shsAverage Volume97,177 shsMarket Capitalization$117.48 millionP/E RatioN/ADividend YieldN/APrice Target$21.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Get Nuvectis Pharma alerts: Email Address Nuvectis Pharma MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside228.1% Upside$21.00 Price TargetShort InterestBearish12.37% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.94Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.05) to ($1.04) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.54 out of 5 starsMedical Sector464th out of 927 stocksPharmaceutical Preparations Industry221st out of 426 stocks 3.5 Analyst's Opinion Consensus RatingNuvectis Pharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageNuvectis Pharma has only been the subject of 1 research reports in the past 90 days.Read more about Nuvectis Pharma's stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted12.37% of the float of Nuvectis Pharma has been sold short.Short Interest Ratio / Days to CoverNuvectis Pharma has a short interest ratio ("days to cover") of 9.7.Change versus previous monthShort interest in Nuvectis Pharma has recently increased by 2.43%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldNuvectis Pharma does not currently pay a dividend.Dividend GrowthNuvectis Pharma does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for NVCT. Previous Next 3.3 News and Social Media Coverage News SentimentNuvectis Pharma has a news sentiment score of 0.94. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.68 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Nuvectis Pharma this week, compared to 1 article on an average week.Search Interest1 people have searched for NVCT on MarketBeat in the last 30 days. MarketBeat FollowsOnly 2 people have added Nuvectis Pharma to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Nuvectis Pharma insiders have not sold or bought any company stock.Percentage Held by Insiders38.85% of the stock of Nuvectis Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions96.77% of the stock of Nuvectis Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Nuvectis Pharma's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Nuvectis Pharma are expected to grow in the coming year, from ($1.05) to ($1.04) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Nuvectis Pharma is -4.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Nuvectis Pharma is -4.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNuvectis Pharma has a P/B Ratio of 9.14. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Nuvectis Pharma's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Brownstone Research My big AI project…On Wednesday, September 25, I’m putting on my first crypto event in two years to unveil: the Perceptron. This is my AI project that I first conceived of shortly after I recommended Nvidia back in 2016.Just click here to register. About Nuvectis Pharma Stock (NASDAQ:NVCT)Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma. It is also developing NXP900, a small molecule drug candidate, which is in Phase 1a clinical trails that inhibits the Proto-oncogene c-Src and YES1 kinases. It has license agreement with the CRT Pioneer Fund for the NXP800 and any of related derivatives; and the University of Edinburgh for the NXP900 and any of associated derivatives. The company was formerly known as Centry Pharma, Inc. and changed its name to Nuvectis Pharma, Inc. in July 2021. Nuvectis Pharma, Inc. was incorporated in 2020 and is based in Fort Lee, New Jersey.Read More NVCT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NVCT Stock News HeadlinesSeptember 16 at 5:16 PM | finance.yahoo.comPESG Releases Report on Nuvectis Pharma: With Summit Therapeutics Threatening to Dethrone Merck's Keytruda, Nuvectis' NXP900 is One to WatchSeptember 5, 2024 | finance.yahoo.comNuvectis Pharma to Present at the H.C. Wainwright 26th Annual Global Investment ConferenceSeptember 16, 2024 | Crypto 101 Media (Ad)This Crypto Coin Could 10x FASTER Than BitcoinThe Bitcoin Halving ignited the 2024 boom, and altcoins are primed to SKYROCKET. Last year we tipped off our community with altcoins that delivered EXPLOSIVE gains. Now, we've uncovered an even bigger potential winner for the 2024 Bitcoin Halving bull run.August 29, 2024 | marketwatch.comNuvectis Shares Rally After Ovarian Cancer Drug Gets FDA's Orphan Drug DesignationAugust 29, 2024 | markets.businessinsider.comNuvectis's NXP800 Granted FDA Orphan Drug Designation For ARID1a-Deficient Ovarian CancersAugust 29, 2024 | globenewswire.comNuvectis Pharma Announces Orphan Drug Designation Granted by the FDA for NXP800 for the Treatment of ARID1a-deficient Ovarian, Fallopian Tube, and Primary Peritoneal CancersAugust 28, 2024 | finance.yahoo.comPositive Signs As Multiple Insiders Buy Nuvectis Pharma StockAugust 6, 2024 | globenewswire.comNuvectis Pharma, Inc. Reports Second Quarter 2024 Financial Results and Business HighlightsSeptember 16, 2024 | Crypto 101 Media (Ad)This Crypto Coin Could 10x FASTER Than BitcoinThe Bitcoin Halving ignited the 2024 boom, and altcoins are primed to SKYROCKET. Last year we tipped off our community with altcoins that delivered EXPLOSIVE gains. Now, we've uncovered an even bigger potential winner for the 2024 Bitcoin Halving bull run.August 2, 2024 | msn.comNuvectis Pharma (NASDAQ: NVCT): 5 Reasons to Keep this Pharma Disruptor on Your RadarAugust 1, 2024 | msn.com5 Reasons Why Nuvectis Pharma (NASDAQ: NVCT) Is a Biopharma Innovator to WatchJuly 28, 2024 | finance.yahoo.comInsiders hold 65% of Nuvectis Pharma, Inc. (NASDAQ:NVCT), and they've been buying recentlyJuly 19, 2024 | theglobeandmail.comNuvectis Pharma Stands Out as a Unique Innovator in the Fast-Growing Precision Medicine MarketMay 28, 2024 | investorplace.com7 Penny Biotech Stocks to Triple Your InvestmentMay 20, 2024 | entrepreneur.comThe Veteran Pharma Founders That Keep Buying Their Own NASDAQ StockMay 16, 2024 | seekingalpha.comNuvectis Pharma: An Interesting Early Pipeline Does Not Justify A BuyMay 16, 2024 | globenewswire.comNuvectis Pharma, Inc. to Present at the H.C. Wainwright BioConnect Investor ConferenceMay 8, 2024 | markets.businessinsider.comStrong Buy Rating for Nuvectis Pharma on Robust Financials and Promising Oncology Drug TrialsSee More Headlines Receive NVCT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Nuvectis Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/06/2024Today9/16/2024Next Earnings (Estimated)11/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:NVCT CUSIPN/A CIK1875558 Webwww.nuvectis.com Phone201-614-3150FaxN/AEmployees8Year FoundedN/APrice Target and Rating Average Stock Price Target$21.00 High Stock Price Target$21.00 Low Stock Price Target$21.00 Potential Upside/Downside+218.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($1.41) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-22,260,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-152.26% Return on Assets-106.23% Debt Debt-to-Equity RatioN/A Current Ratio3.17 Quick Ratio3.17 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.70 per share Price / Book9.43Miscellaneous Outstanding Shares18,356,000Free Float11,225,000Market Cap$121.15 million OptionableNot Optionable Beta0.47 10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free Report Key ExecutivesMr. Ron Bentsur M.B.A. (Age 58)Co-Founder, Chairman, CEO & President Comp: $1.12MDr. Enrique Poradosu Ph.D. (Age 57)Co-Founder, Executive VP, Chief Scientific & Business Officer Comp: $705.5kMr. Shay Shemesh (Age 40)Co-Founder, Executive VP, Chief Development & Operations Officer Comp: $705.5kMr. Michael Carson CPA (Age 48)Vice President of Finance Key CompetitorsCOMPASS PathwaysNASDAQ:CMPSContineum TherapeuticsNASDAQ:CTNMTourmaline BioNASDAQ:TRMLSage TherapeuticsNASDAQ:SAGEAura BiosciencesNASDAQ:AURAView All CompetitorsInsiders & InstitutionsPoint72 Asia Singapore Pte. Ltd.Bought 9,203 shares on 9/16/2024Ownership: 0.050%Point72 Asia Singapore Pte. Ltd.Bought 9,203 shares on 8/15/2024Ownership: 0.050%Marshall Wace LLPSold 16,200 shares on 8/14/2024Ownership: 0.185%Renaissance Technologies LLCBought 12,800 shares on 8/9/2024Ownership: 0.406%Baxter Bros Inc.Bought 12,500 shares on 7/16/2024Ownership: 0.068%View All Insider TransactionsView All Institutional Transactions NVCT Stock Analysis - Frequently Asked Questions How have NVCT shares performed this year? Nuvectis Pharma's stock was trading at $8.34 at the start of the year. Since then, NVCT stock has decreased by 23.3% and is now trading at $6.40. View the best growth stocks for 2024 here. How were Nuvectis Pharma's earnings last quarter? Nuvectis Pharma, Inc. (NASDAQ:NVCT) posted its quarterly earnings data on Tuesday, August, 6th. The company reported ($0.26) EPS for the quarter, meeting the consensus estimate of ($0.26). When did Nuvectis Pharma IPO? Nuvectis Pharma (NVCT) raised $19 million in an initial public offering (IPO) on Friday, February 4th 2022. The company issued 3,200,000 shares at $5.00-$7.00 per share. Who are Nuvectis Pharma's major shareholders? Nuvectis Pharma's top institutional investors include Baldwin Brothers LLC MA (0.92%), Renaissance Technologies LLC (0.41%), Marshall Wace LLP (0.18%) and Baxter Bros Inc. (0.07%). Insiders that own company stock include Marlio Charles Mosseri, Enrique Poradosu, Shay Shemesh and Kenneth Hoberman. View institutional ownership trends. How do I buy shares of Nuvectis Pharma? Shares of NVCT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:NVCT) was last updated on 9/16/2024 by MarketBeat.com Staff From Our Partners44-year Wall Street Vet: “Permanent devastation is coming to America”After 44 years on Wall Street, I've seen it all... Black Monday, the Great Recession, the Covid crash. B...InvestorPlace | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredIntroducing the PerceptronOn Wednesday, September 25, I’m putting on my first crypto event in two years to unveil: the Perceptron. Th...Brownstone Research | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredTrump’s weapon lurks in abandoned AmericaUnemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. ...Porter & Company | SponsoredUnlock the Secret to Easy Wins with Iron CondorsDiscover the power of Iron Condor trades – a low-risk, high-reward strategy that allows you to profit consiste...Netpicks | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | SponsoredNvidia needs these 3 companies on a new $1 trillion SuperprojectNvidia is pivoting to a new $1 trillion Superproject that could revolutionize the AI industry… again. And i...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nuvectis Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Nuvectis Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
